沙特阿拉伯的药剂师和医生对生物类似药物的知识,态度和实践:一个广泛的审查

相关实验视频

Updated: Jan 13, 2026

05:02

Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases

Published on: October 24, 2019

33.5K

Abdulrhman Alanizi^1,2, Reema Alotaibi², Ranad Babalghaith²

¹Pharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital, Riyadh, SAU.

Cureus

|October 28, 2025

概括

沙特阿拉伯的医疗保健提供者对生物类似药有充分的知识和积极的态度. 然而,监管知识的差距需要有针对性的教育,以改善这些成本效益的治疗方法的采用.

科学领域:

药物经济学药物经济学
医疗保健服务研究医疗服务研究
药物监管药物监管药物监管

背景情况:

生物仿制药提供了具有成本效益的替代品,提高了患者获得治疗的机会.
最近在沙特阿拉伯批准生物类似药需要了解医疗保健提供者的观点.
优化生物类似药的利用需要医生和药剂师之间充分的知识和积极的态度.

研究的目的:

探索沙特阿拉伯药剂师和医生的关于生物类似药的知识,态度和实践 (KAP).
确定影响生物类似药在临床实践中的采用因素.
为改善沙特卫生保健系统中生物类似药物利用的战略提供信息.

主要方法:

根据PRISMA协议进行了范围审查.
在主要数据库 (PubMed,MEDLINE,EMBASE,Scopus,Google Scholar) 搜索了2015-2024年期间的研究.
包括59项鉴定中的10项研究,重点关注医疗保健提供者的KAP与生物类似药有关.

主要成果:

48%-70%的从业者表现出对生物类似药的充分知识.
超过60%的医疗保健提供者对生物类似药物表现出积极的态度.
熟悉临床证据,医疗专业和监管清晰度影响了生物类似药的采用.

结论:

虽然知识和态度通常是积极的,但监管理解存在差距.
有针对性的教育计划对于加强生物类似药的采用至关重要.
建议采取政策干预措施,以进一步改善生物类似药在沙特阿拉伯的临床实践中的整合.

关键词:

他们的态度和态度.生物类似药的生物类似药.医疗保健提供者提供医疗保健.知识的知识知识的知识.知识态度实践 (kap) 的知识态度实践.药剂师是药剂师,药剂师是药剂师.医生是医生,医生是医生实践实践实践实践实践沙特阿拉伯沙特阿拉伯范围审查范围审查审查

相关概念视频

01:28

Drug Products: Biologics, Biosimilars and Interchangeables

229

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

229

01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

143

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

143

01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

171

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...

171

01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

147

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...

147

01:16

Bioequivalence: Overview

1.8K

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...